Click4Assistance UK Live Chat Software
Helpline01322 619898

Recruitment for people with severe asthma to join Patient Working Group extended


3TR, a European project which aims to develop a patient-centred definition of response to biological therapy for severe asthma, is looking for patients with severe asthma to join its Patient Working Group.

This group is coordinated by European Lung Foundation and European Federation of Allergy and Airways Diseases Patients’ Associations. The 3TR project aims to improve the care of patients with severe asthma across Europe.

The group will support researchers to develop a patient-centred definition of response to biological treatments for severe asthma.

Biological treatments are injected medications such as omalizumab [Xolair], mepolizumab [Nucala], reslizumab [Cinquero], benralizumab [Fasenra], dupilumab [Dupixent]). Currently, there is no agreement about what counts as ‘responding’ to biological treatment – for example, how much better a patient must feel, or what improvement in their lung function is needed.

Defining a response will help clinicians understand if a biological treatment is working or not for patients with severe asthma. In the future, doctors and patients will be able to use this definition to decide whether a biological treatment should be continued or if alternative treatments should be used instead.

Who can take part?

You can apply to participate if:

  • You are 12 years of age or above and have severe asthma
  • You are a parent or carer of a person with severe asthma who is 6 years of age or above
  • Ideally previously taken / currently taking biological therapy (but not mandatory for participation)
  • Able to read and communicate in English
  • No specific skills are required


An introductory call with interested patients will be organised to provide more information about the project and activities. The Patient Working Group will meet by video-conference (1 hour) once a month.

Interested patients can apply to participate by 30 August 2021 by sending an email to Dr Kate Khaleva, University of Southampton:

You can find out more about 3TR here.

Share this news story